The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of September. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ADLYXIN (Lixisenatide) X X   X   X    
DIACOMIT (Stiripentol) X X   X        
DUPIXENT (Dupilumab) X X       X    
EFFEXOR XR (Venlafaxine HCl ext-rel)   X   X X      
IMFINZI (Durvalumab) X X   X        
OCTAGAM 5% (Immune globulin [human])   X X X X      
QUARTETTE (Levonorgestrel, ethinyl estradiol)     X X X      
RETEVMO (Selpercatinib) X X   X X X    
TRODELVY (Sacituzumab govitecan-hziy) X   X        
ULTOMIRIS (Ravulizumab-cwvz)   X   X     X  
Review more drug monograph updates